Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.
Nikonenko
Boris V
BV
Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850, USA. borisnikonenko@sequella.com
Protopopova
Marina
M
Samala
Rowena
R
Einck
Leo
L
Nacy
Carol A
CA
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D032761:Animal Experimentation; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005029:Ethylenediamines / Q000494:pharmacology / Q000627:therapeutic use*; D008168:Lung; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D005029:Ethylenediamines; C506841:N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine; D000218:Adamantane